Australia's most trusted
source of pharma news
Wednesday, 20 August 2025
Posted 15 August 2025 AM
As Novo Nordisk continues to phase out some older generation insulin products, the TGA has provided an update on the availability of certain brands in Australia.
The global strategy first announced last year is not related to product safety, quality or effectiveness rather a move to streamline their insulin offerings. It is occurring gradually, with some products already phased out while others will be discontinued by late 2026.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.